SEARCH

SEARCH BY CITATION

References

  • 1
    Ahlberg, Å. (1965) Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthopaedica Scandinavica, 77, (Suppl.), 198.
  • 2
    Aledort, L.M., Haschemeyer, R.H. & Pettersson, H. (1994) A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. Journal of Internal Medicine, 236, 391399.
  • 3
    Berntorp, E. (1995) Methods of hemophilia care delivery; regular prophylaxis vs. episodic treatment. Haemophilia, 1, (Suppl. 1), 37.
  • 4
    Berntorp, E., Ekman, M., Gunnarsson, M. & Nilsson, I.M. (1996) Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia, 2, 9599.
  • 5
    Blanchette, V.S., Al-Musa, A., Stain, A.M., Ingram, J. & Fille, R.M. (1997) Central venous access devices in children with hemophilia: an up-date. Blood Coagulation and Fibrinolysis, 8, (Suppl. 1), S11S14.
  • 6
    Bohn, R.L., Avorn, J., Glynn, R.J., Choodnovskiy, I., Haschemeyer, R. & Aledort, L.M. (1998) Prophylactic use of factor VIII: an economic evaluation. Thrombosis and Haemostasis, 79, 932937.
  • 7
    Carlsson, M., Björkman, S. & Berntorp, E. (1998) Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia, 4, 8388.
  • 8
    Liesner, R.J., Khair, K. & Hann, I.M. (1996) The impact of prophylactic treatment on children with severe haemophilia. British Journal of Haematology, 92, 973978.DOI: 10.1046/j.1365-2141.1996.420960.x
  • 9
    Ljung, R., Van Den Berg, M., Petrini, P., Tengborn, L., Scheibel, E., Kekomäki, R. & Effenberg, W. (1998) Port-A-Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatrica, 87, 10511054.DOI: 10.1080/080352598750031365
  • 10
    Löfqvist, T., Nilsson, I.M., Berntorp, E. & Pettersson, H. (1997) Haemophilia prophylaxis in young patients: a long-term follow-up. Journal of Internal Medicine, 241, 395400.DOI: 10.1046/j.1365-2796.1997.130135000.x
  • 11
    Lusher, J. (1997) Prophylaxis in children with hemophilia: is it the optimal treatment? Thrombosis and Haemostasis, 78, 726729.
  • 12
    Manco-Johnson, M.J., Nuss, R., Geraghty, S., Funk, S. & Kilcoyne, R. (1994) Results of secondary prophylaxis in children with severe hemophilia. American Journal of Hematology, 47, 113117.
  • 13
    Nilsson, I.M., Berntorp, E., Löfqvist, T. & Pettersson, H. (1992) Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B. Journal of Internal Medicine, 232, 2532.
  • 14
    Petrini, P., Lindvall, N., Egberg, N. & Blombäck, M. (1991) Prophylaxis with factor concentrate in preventing hemophilic arthropathy. American Journal of Pediatric Hematology/Oncology, 13, 280287.
  • 15
    Rosén, S. (1984) Assay of factor VIII:C with a chromogenic substrate. Scandinavian Journal of Haematology, 33, (Suppl. 40), 139145.
  • 16
    Smith, P.S., Teutsch, S.M., Schaffer, P.A., Rolka, H. & Evatt, B. (1996) Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. Journal of Paediatrics, 129, 424431.
  • 17
    Szucs, T.D., Öffner, A. & Schramm, W. (1996) Socioeconomic impact of haemophilia care: results of a pilot study. Haemophilia, 2, 211217.
  • 18
    Van Den Berg, H.M., Nieuwenhuis, H.K., Mauser-Bunchoten, E.P. & Rosendaal, G. (1994) Haemophilia prophylaxis in the Netherlands. Seminars in Haematology, 31, (Suppl. 2), 1315.